Monte Rosa Therapeutics (GLUE) News
NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
8.64-0.27 (-3.03%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GLUE news summary
We found 6 recent headlines mentioning Monte Rosa Therapeutics (GLUE): 0 in the past week and 6 in the past 30 days, most often from GlobeNewswire, Seeking Alpha, Nasdaq. For price context, GLUE is down 3.03% at $8.64. The most recent story, "Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout", was published by GlobeNewswire on Nov 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Monte Rosa Therapeutics headlines
- Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in GoutMonte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in GoutGlobeNewswire
- Monte Rosa Therapeutics reports Q3 resultsSeeking Alpha
- Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesMonte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswire
- Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Monte Rosa's MRT-6160 Enters Phase 2 Trial For Moderate To Severe Psoriatic Arthritis; Stock Up(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) announced that Novartis has initiated a second Phase 2 clinical study of MRT-6160 (DDY391), its investigational VAV1-directed molecular glue degrader,…NasdaqGLUE, NVS, HEI.A
- Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue DegraderGlobeNewswire